Stay updated on Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page
- Check2 days agoChange Detected- Added: Revision: v3.0.2. - Removed: Revision: v3.0.1 and a 'Back to Top' element. Overall, this is a small update to versioning metadata and a minor navigation change.SummaryDifference0.1%
- Check9 days agoChange DetectedThe page now includes the full MK-7684A-002 (KEYVIBE-002) trial details, including design, treatment arms (Pembrolizumab/Vibostolimab coformulation with/without Docetaxel vs placebo plus Docetaxel), outcomes, eligibility, enrollment, and completion status, plus a global list of trial sites, sponsor information, results posting dates, IPD sharing plans, and protocol links. This update significantly expands core content with proper nouns and logistical details, while deletions are limited to a version reference, indicating a major information addition rather than removal.SummaryDifference100%
- Check16 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while extensive details about study criteria, locations, and descriptions have been removed.SummaryDifference89%
- Check23 days agoNo Change Detected
- Check24 days agoChange DetectedThe page has removed the phrase 'Last Update Posted (Estimated)' and replaced it with 'Last Update Posted'.SummaryDifference0.0%
- Check31 days agoChange DetectedThe webpage has been updated to reflect new registry identifiers and updated timelines for adverse events (AEs) in clinical studies, with the last update date changed to 2025-07-30.SummaryDifference1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.